Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 12, 2009, Pages 920-926

  Armenian, Saro H ^a   Nash, Kevin A ^b,c   Kapoor, Neena ^b,c   Franklin, Janet L ^c   Gaynon, Paul S ^b,c   Ross, Lawrence A ^b,c   Hoffman, Jill A ^b,c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aspergillus; Galactomannan; Pediatrics; Polymerase chain reaction; Prospective screening

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECHINOCANDIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FUNGAL DNA; GALACTOMANNAN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MICAFUNGIN; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE; MANNAN; RNA 28S;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANCER PATIENT; CHILD; CHILDHOOD LEUKEMIA; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; SCREENING TEST; TREATMENT OUTCOME; ALLOTRANSPLANTATION; BLOOD; BLOOD DISEASE; CASE REPORT; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; ASPERGILLOSIS; ASPERGILLUS; CHILD; CHILD, PRESCHOOL; DNA, FUNGAL; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MANNANS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RISK FACTORS; RNA, RIBOSOMAL, 28S; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 73949145147     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b83e77     Document Type: Article

References (45)

1. Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006;25:634-639.
2. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in hematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173-180.
3. Dvorak CC, Steinbach WJ, Brown JM, et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-629.
4. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
5. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-379.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
7. Nosari A, Oreste P, Cairoli R, et al. Invasive aspergillosis in hematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol. 2001; 68:231-236.
8. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531-540.
9. Armenian SH, La Via WV, Siegel SE, et al. Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. Pediatr Blood Cancer. 2007;48:165-172.
10. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Medical Mycology. 2006;44:S199-S205.
11. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297-1306.
12. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005; 41:1242-1250.
13. Chamilos G, Kontoyiannis D. Defining the diagnosis of invasive aspergillosis. Medical Mycology. 2006;44:S163-S172.
14. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
15. Maertens J, Verhaegen J, Demuynck H, et al. Autopsycontrolled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol. 1999;37:3223-3228.
16. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42:487-489.
17. Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis. 2006;193:741-747.
18. Hebart H, Loffler J, Meisner C, et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis. 2000; 181:1713-1719.
19. Buchheidt D, Baust C, Skladny H, et al. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol. 2002;116:803-811.
20. White PL, Archer AE, Barnes RA. Comparison of nonculture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol. 2005;43:2181-2187.
21. White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis. 2006;42: 479-486.
22. Hovi L, Saxen H, Saarinen-Pihkala UM, et al. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007;48:28-34.
23. Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007;26:558-564.
24. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001;91:311-318.
25. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;20:1898-1906.
26. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:9.
27. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
28. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641-649.
29. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis. 2007;59: 407-414.
30. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis. 2003;16: 521-526.
31. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005;41:521-526.
32. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
33. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
34. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J. 1996;15:232-237.
35. Hayden R, Pounds S, Knapp K, et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J. 2008;27:815-819.
36. El-Mahallawy HA, Shaker HH, Ali Helmy H, et al. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk pediatric cancer patients. Med Mycol. 2006;44:733-739.
37. Das A, Shah A, Ross LA, et al. Invasive aspergillosis in infants and children. Presented at St. Jude's/PID Pediatric Microbial Research Conference. 2002.
38. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
39. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762-1769.
40. Mennink-Kersten MA, Klont RR, Warris A, et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet. 2004;363:325-327.
41. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol. 2005;43:3925-3931.
42. Siemann M, Koch-Dorfler M. The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergillosis (IPA). Mycoses. 2001;44:266-272.
43. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin Infect Dis. 2004;38: 913-916.
44. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillintazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol. 2004;42:4744-4748.
45. Lass-Florl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol. 2004;42:4154-4157.